However, we observed notably increased incidence risks of gastric ulcer and intestinal obstruction (Supporting Information, Figure 1S and 2S) associated with GLP‐1 RAs use without PSM, particularly after 1 year of treatment. Here, GLP1R is linked to intestinal obstruction.